The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition
There is a need to improve and extend the use of clinically-approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-negative breast cancer (TNBC). The demonstration that ruthenium(II) polypyridyl complex (RPC) metallo-intercalators can rapidly stall DNA re...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Chemical Society
2020
|
| _version_ | 1797074812959457280 |
|---|---|
| author | Yusoh, NA Leong, SW Chia, SL Harun, SN Rahman, MB Vallis, KA Gill, MR Ahmad, H |
| author_facet | Yusoh, NA Leong, SW Chia, SL Harun, SN Rahman, MB Vallis, KA Gill, MR Ahmad, H |
| author_sort | Yusoh, NA |
| collection | OXFORD |
| description | There is a need to improve and extend the use of clinically-approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-negative breast cancer (TNBC). The demonstration that ruthenium(II) polypyridyl complex (RPC) metallo-intercalators can rapidly stall DNA replication fork progression provides the rationale for their combination alongside DNA damage response (DDR) inhibitors to achieve synergism in cancer cells. The aim of the present study was to evaluate use of the multi-intercalator [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2′,3′-c]phenazine, PIP = (2-(phenyl)imidazo[4,5-f][1,10]phenanthroline, Ru-PIP) alongside the PARP inhibitors (PARPi) olaparib and NU1025. Cell proliferation and clonogenic survival assays indicated a synergistic relationship between Ru-PIP and olaparib in MDA-MB-231 TNBC and MCF7 human breast cancer cells. Strikingly, low dose Ru-PIP renders both cell lines hypersensitive to olaparib, with a 300-fold increase in olaparib potency in TNBC; the largest non-genetic PARPi enhancement effect described to date. Negligible impact on the viability of normal human fibroblasts was observed for any combination tested. Increased levels of DNA double-strand break (DSB) damage and olaparib abrogation of Ru-PIP activated pChk1 signalling is consistent with PARPi-facilitated collapse of Ru-PIP-associated stalled replication forks. This results in enhanced G2/M cell-cycle arrest, apoptosis and decreased cell motility for the combination treatment compared to single-agent conditions. This work establishes that an RPC metallo-intercalator can be combined with PARPi for potent synergy in BRCA-proficient breast cancer cells, including TNBC. |
| first_indexed | 2024-03-06T23:41:38Z |
| format | Journal article |
| id | oxford-uuid:6f87ce75-4a70-4fac-8582-f89c73f7f119 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:41:38Z |
| publishDate | 2020 |
| publisher | American Chemical Society |
| record_format | dspace |
| spelling | oxford-uuid:6f87ce75-4a70-4fac-8582-f89c73f7f1192022-03-26T19:31:08ZThe metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibitionJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:6f87ce75-4a70-4fac-8582-f89c73f7f119EnglishSymplectic Elements at OxfordAmerican Chemical Society2020Yusoh, NALeong, SWChia, SLHarun, SNRahman, MBVallis, KAGill, MRAhmad, HThere is a need to improve and extend the use of clinically-approved poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi), including for BRCA wild-type triple-negative breast cancer (TNBC). The demonstration that ruthenium(II) polypyridyl complex (RPC) metallo-intercalators can rapidly stall DNA replication fork progression provides the rationale for their combination alongside DNA damage response (DDR) inhibitors to achieve synergism in cancer cells. The aim of the present study was to evaluate use of the multi-intercalator [Ru(dppz)2(PIP)]2+ (dppz = dipyrido[3,2-a:2′,3′-c]phenazine, PIP = (2-(phenyl)imidazo[4,5-f][1,10]phenanthroline, Ru-PIP) alongside the PARP inhibitors (PARPi) olaparib and NU1025. Cell proliferation and clonogenic survival assays indicated a synergistic relationship between Ru-PIP and olaparib in MDA-MB-231 TNBC and MCF7 human breast cancer cells. Strikingly, low dose Ru-PIP renders both cell lines hypersensitive to olaparib, with a 300-fold increase in olaparib potency in TNBC; the largest non-genetic PARPi enhancement effect described to date. Negligible impact on the viability of normal human fibroblasts was observed for any combination tested. Increased levels of DNA double-strand break (DSB) damage and olaparib abrogation of Ru-PIP activated pChk1 signalling is consistent with PARPi-facilitated collapse of Ru-PIP-associated stalled replication forks. This results in enhanced G2/M cell-cycle arrest, apoptosis and decreased cell motility for the combination treatment compared to single-agent conditions. This work establishes that an RPC metallo-intercalator can be combined with PARPi for potent synergy in BRCA-proficient breast cancer cells, including TNBC. |
| spellingShingle | Yusoh, NA Leong, SW Chia, SL Harun, SN Rahman, MB Vallis, KA Gill, MR Ahmad, H The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title | The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title_full | The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title_fullStr | The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title_full_unstemmed | The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title_short | The metallo-intercalator [Ru(dppz)2(PIP)]2+ renders BRCA wild-type triple-negative breast cancer cells hypersensitive to PARP inhibition |
| title_sort | metallo intercalator ru dppz 2 pip 2 renders brca wild type triple negative breast cancer cells hypersensitive to parp inhibition |
| work_keys_str_mv | AT yusohna themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT leongsw themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT chiasl themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT harunsn themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT rahmanmb themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT valliska themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT gillmr themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT ahmadh themetallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT yusohna metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT leongsw metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT chiasl metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT harunsn metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT rahmanmb metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT valliska metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT gillmr metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition AT ahmadh metallointercalatorrudppz2pip2rendersbrcawildtypetriplenegativebreastcancercellshypersensitivetoparpinhibition |